Based on Clemson University research, 3D cancer cell modelling spinout Kiyatec has increased its total financing to $14.9m with the help of clinical lab operator LabCorp and VC firm VentureSouth.
Kiyatec, a US-based cancer cytology modelling spinout of Clemson University, obtained an initial $3m in series B2 funding on Wednesday led by VC firm VentureSouth and backed by clinical laboratory operator LabCorp.
Founded in 2005, Kiyatec has developed a technology called 3D-Predict that provides ex vivo predictive modelling of live cancer cells in 3D cell culture environments.
Kiyatec’s platform helps inform patient-specific clinical decisions when prescribing cancer therapies and also supports the development of new drugs.
The series B2 capital will help Kiyatec continue an ongoing clinical study of its technology in evaluating the patient-specific response of solid tumours to oncological therapies.
Kiyatec has now raised $14.9m in equity and debt financing, $200,000 of which was debt, according to regulatory filings. The documents show Kiyatec last obtained $5.3m of a targeted $14.3m equity round from undisclosed backers in March 2019, after a $3.2m equity round some…
